METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES

Ming-Shi Chang (Inventor)

Research output: Patent

Abstract

Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.
Original languageEnglish
Patent number9127066
Publication statusPublished - 1800

Fingerprint

Osteoporosis
Antibodies
Diabetic Nephropathies
Nucleic Acids
Renal Insufficiency
interleukin-20 receptor

Cite this

@misc{7563c45ec4ee42d08cb36eaa977735ed,
title = "METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES",
abstract = "Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.",
author = "Ming-Shi Chang",
year = "1800",
language = "English",
type = "Patent",
note = "9127066",

}

TY - PAT

T1 - METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES

AU - Chang, Ming-Shi

PY - 1800

Y1 - 1800

N2 - Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

AB - Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

M3 - Patent

M1 - 9127066

ER -